Veeva Brings Artificial Intelligence to Drug Safety
Summary
PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva Systems (NYSE:VEEV) today announced Veeva Vault Safety.AI, a new artificial intelligence (AI) application that automates case intake to reduce the time and effort of manual data entry for more efficient case processing. “There is a significant opportunity to reduce the number of manual processes in drug safety,” said Dr. Lisa Hornick, chief medical officer at Catalyst Clinical Research, a global CRO providing flexible, customized, clinical research solutions to the biopharmaceutical industry. “Using artificial intelligence to automate case intake will speed case processing and allow our pharmacovigilance organization to spend less time on data entry.” Life sciences companies are collecting an increasing volume of adverse events from an expanding number of sources, including social media, fax, email, literature, and call center notes. “The high cost and manual effort of case intake processes are no longer sustainable, making it an area that is ripe for innovation,” said Brian Longo, SVP & GM, Veeva Vault Safety. “Veeva Vault Safety.AI automates data entry so medical professionals can focus their efforts on verification and pharmacovigilance organizations can drive greater efficiency in drug safety operations.” Safety.AI is planned for availability in April 2020.
Classifications
AskAI Classifications
LabelsLinked Companies
